---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Renin-Angiotensin system inhibitors and blood pressure control"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Renin-Angiotensin system inhibitors and blood pressure control. Topics: Blood pressure target: KDIGO 2024 CKD guideline, Renin-angiotensin system inhibitor recommendations: KDIGO 2024 CKD guideline, Supportive treatment for FSGS: KDIGO 2021 glomerular diseases guideline, Blood pressure control after a high-risk APOL1 genotype is confirmed: Delphi consensus, and 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/renin-angiotensin-system-inhibitors-and-blood-pressure-control"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Renin-Angiotensin system inhibitors and blood pressure control

<a id="heading-2.2.2.1.1"></a>

## 2.2.2.1.1 Renin-Angiotensin System Inhibitors and Blood Pressure Control

<a id="topic-2.2.2.1.1-1"></a>

### Blood pressure target: KDIGO 2024 CKD guideline

> “Recommendation 3.4.1: We suggest that adults with high BP and CKD be treated with a target systolic blood pressure (SBP) of <120 mm Hg, when tolerated, using standardized office BP measurement (2B).”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.1-2"></a>

### Renin-angiotensin system inhibitor recommendations: KDIGO 2024 CKD guideline

> “Recommendation 3.6.1: We recommend starting renin-angiotensin-system inhibitors (RASi) (angiotensin-converting enzyme inhibitor [ACEi] or angiotensin II receptor blocker [ARB]) for people with CKD and severely increased albuminuria (G1–G4, A3) without diabetes (1B).”
> “Recommendation 3.6.2: We suggest starting RASi (ACEi or ARB) for people with CKD and moderately increased albuminuria (G1–G4, A2) without diabetes (2C).”
> “Recommendation 3.6.3: We recommend starting RASi (ACEi or ARB) for people with CKD and moderately-to-severely increased albuminuria (G1–G4, A2 and A3) with diabetes (1B).”
> “Recommendation 3.6.4: We recommend avoiding any combination of ACEi, ARB, and direct renin inhibitor (DRI) therapy in people with CKD, with or without diabetes (1B).”
> “Practice Point 3.6.1: RASi (ACEi or ARB) should be administered using the highest approved dose that is tolerated to achieve the benefits described because the proven benefits were achieved in trials using these doses.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.1-3"></a>

### Supportive treatment for FSGS: KDIGO 2021 glomerular diseases guideline

> “Adult patients with FSGS should receive the necessary supportive treatment as advised for all patients with persistent proteinuria (Chapter 1), including the use of RAS blockade, optimal BP control, and dietary salt restriction.”

Source: [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)

<a id="topic-2.2.2.1.1-4"></a>

### Blood pressure control after a high-risk APOL1 genotype is confirmed: Delphi consensus

> “After a patient with CKD is confirmed to have a high-risk APOL1 genotype, the clinician should:”
> “Inform the patient about other modifiable risk factors and renoprotective measures (lifestyle changes, BP control)”

Source: [Freedman et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8425659/)

<a id="topic-2.2.2.1.1-5"></a>

### Blood pressure goal and ACE inhibitor effects by APOL1 genotype in AASK

> “In the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; P<0.001). There was no interaction between APOL1 status and trial interventions or the presence of baseline proteinuria.”
> “there was no significant interaction between APOL1 status and the randomized blood-pressure goal with respect to the progression of chronic kidney disease (P = 0.72 for interaction)”
> “The lack of significant interaction between APOL1 and treatment with an ACE inhibitor suggests that patients in the APOL1 high-risk group still benefit from this class of drugs.”

Source: [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/)

<a id="topic-2.2.2.1.1-6"></a>

### Strict blood pressure control and mortality by APOL1 genotype in AASK

> “This included 682 participants with known APOL1 genotype (157 with high-risk genotype) previously assigned to either strict (mean arterial pressure [MAP] 92 mm Hg or less) versus usual blood pressure control (MAP 102-107 mm Hg) during the trial.”
> “In the APOL1 high-risk group, risk of death was 42% lower comparing strict versus usual blood pressure control (0.58 [0.35-0.97]). In the APOL1 low-risk group, risk of death comparing strict versus usual blood pressure control was not significantly different (1.09 [0.84-1.43]).”

Source: [Ku et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5237400/)

<a id="topic-2.2.2.1.1-7"></a>

### Real-world use of RAAS inhibitors, SGLT2 inhibitors, and other drug classes in AMKD

> “Within the study period, 35.7% of patients had at least 1 administration or fill of a RAAS inhibitor, 35% of a calcium channel blocker, 27.9% of a beta blocker, 10.5% of an SGLT2 inhibitor, and 4.4% of a GLP-1 receptor agonist.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
